^
Association details:
| Biomarker: | ALK rearrangement |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | tanespimycin (BMS-722782) (HSP90 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer
Excerpt:
ALK rearranged cancer cell lines are sensitive to heat-shock protein 90 (Hsp90) inhibitors. (A) Cancer cell lines with epidermal growth factor receptor (EGFR) mutations (H1975, L858R/T790M, and HCC827 exon 19 deletion) or ALK gene rearrangement (H3122 and MGH-006) were treated with increasing doses of the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) for 24 hours.
DOI:
10.1200/JCO.2010.30.8338
